Value of Precision Medicine in Advanced Non‐Small Cell Lung Cancer: Real‐World Outcomes Associated with the Use of Companion Diagnostics

BACKGROUND: Companion diagnostic (CDx) testing for patients with advanced non‐small cell lung cancer (aNSCLC) identifies patients more likely to benefit from biomarker‐driven treatments. METHODS: Patients with nonsquamous cell (non‐Sq) aNSCLC from the Flatiron Health database (diagnosed January 1, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Ani, Shah, Roma A., Wong, William B., Schneider, Charles E., Alexander, Marliese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648341/
https://www.ncbi.nlm.nih.gov/pubmed/32627882
http://dx.doi.org/10.1634/theoncologist.2019-0864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648341/
https://www.ncbi.nlm.nih.gov/pubmed/32627882
http://dx.doi.org/10.1634/theoncologist.2019-0864

Ejemplares similares